Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03455959 · ClinicalTrials.gov registry record · NA
Lung-Resident Memory Th2 Cells in Asthma
A NA study of Asthma, Allergic, sponsored by Andrew D. Luster, M.D.,Ph.D..
- Active
- Registry status
- NA
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT03455959: Active NA study of Asthma, Allergic, sponsored by Andrew D. Luster, M.D.,Ph.D..
NCT03455959 is a NA study of Asthma, Allergic that is active but no longer recruiting, run by Andrew D. Luster, M.D.,Ph.D.. The registered enrollment target is 37 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03455959, a NA study of Asthma, Allergic, is active but no longer recruiting, sponsored by Andrew D. Luster, M.D.,Ph.D..
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
Determining how memory T helper type 2 (Th2) initiate recall responses to aeroallergens has the potential to change the therapeutic approach to allergic asthma, the most common asthma subtype. \~5-10% of effector Th2 cells recruited into the lung give rise to long-lived tissue resident memory cells that are poised to respond upon allergen re-exposure.Consequently, targeting memory Th2 cell activation is an attractive therapeutic strategy. However, it is not well understood how allergen inhalation initiates a memory Th2 cell response in the lung. The focus of this new study on the role of lung-resident memory Th2 cells in orchestrating the recall response to allergen in the lung, including the recruitment and activation of circulating Th2 cells, is a natural, timely and exciting extension of the investigators' ongoing Allergen Challenge Protocol.
Primary Outcome
The investigators will determine the phenotype of Th2-Trm recovered from the airway mucosa of humans with asthma via flow cytometry to define the phenotype of human Th2-Trm. The T cells will be recovered from airway bronchial brushing samples of patients with allergic asthma and allergy to an indoor allergen, and the investigators will obtain comparative samples from nonallergic healthy control subjects.
Conditions Studied
Interventions
- PROCEDURE Bronchoscopy/BAL
- PROCEDURE Airway Brushing
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2019-05-23 |
| Est. Completion | 2025-12-15 |
| Phase | NA |
What the registry record for NCT03455959 still lists
NCT03455959 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Asthma, Allergic appearing as the primary indexed condition, and to 2 interventions - of which Bronchoscopy/BAL is the first listed.
NCT03455959 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03455959 about?
NCT03455959 is a clinical study titled "Lung-Resident Memory Th2 Cells in Asthma". Determining how memory T helper type 2 (Th2) initiate recall responses to aeroallergens has the potential to change the therapeutic approach to allergic asthma, the most common asthma subtype. \~5-10% of effector Th2 cells recruited into the lung give rise to long-lived tissue resident memory cells ...
What is the current status of trial NCT03455959?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 37 participants. The study started on 2019-05-23. Estimated completion is 2025-12-15.
What conditions does trial NCT03455959 study?
This clinical trial studies the following conditions: Asthma, Allergic.
What interventions are being tested in trial NCT03455959?
The interventions under investigation include: Bronchoscopy/BAL (PROCEDURE), Airway Brushing (PROCEDURE).
Who is sponsoring clinical trial NCT03455959?
This trial is sponsored by Andrew D. Luster, M.D.,Ph.D., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03455959 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma, Allergic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03455959's enrollment target sits among peer trials
37 1540th of 2000 higher than 460 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI